STOCK TITAN

United Therapeutics director sells 228 shares

Director Nilda Mesa exercised options and sold 228 UTHR shares on September 14, 2026 in open-market style transactions not reported under a Rule 10b5-1 plan.

(Moderate)
(Negative)
Form Type
4

Rhea-AI Filing Summary

UNITED THERAPEUTICS Corp (UTHR) director Nilda Mesa exercised stock options for 130 shares of common stock on September 14, 2026 at an exercise price of $110.86 per share, then sold a total of 228 shares in two transactions at prices around $505.8 per share. Following the option exercise, she held 6,430 stock options directly, and no transactions were reported under a Rule 10b5-1 trading plan.

Positive

  • None.

Negative

  • None.
Insider Mesa Nilda
Role Director
Sold 228 shs ($115K)
Approx. gross sale proceeds $115K
Approx. exercise cost $14K
Type Security Shares Price Value
Exercise Stock Option 130 $0.00 $0.00
Exercise Common Stock 130 $110.86 $14K
Sale Common Stock F1 130 $505.7868 $66K
Sale Common Stock 98 $505.975 $50K
Holdings After Transaction: Stock Option — 6,430 contracts (Direct); Common Stock — 5,580 shares (Direct)
Footnotes (1)
  1. F1. This transaction was executed in multiple trades at prices ranging from $505.76 to $505.985. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.
Options exercised 130 shares Stock options for UNITED THERAPEUTICS common stock exercised on September 14, 2026
Exercise price $110.86 per share Exercise price of stock options converted into 130 shares of common stock
Shares sold (total) 228 shares Common stock sales on September 14, 2026
Sale price (weighted average) $505.7868 per share Weighted average price for 130-share sale, with trades between $505.76 and $505.985
Sale price (second trade) $505.9750 per share Price for 98-share common stock sale on September 14, 2026
Options held after transaction 6,430 options Total stock options following the reported option exercise
Option expiration date October 31, 2028 Expiration date of the stock options exercised for 130 shares
derivative security financial
"described as an exercise or conversion of a derivative security into common stock"
A derivative security is a financial contract whose value comes from the price or performance of something else, such as a stock, bond, commodity, or market index. For investors it acts like an insurance policy or a wager: it can be used to protect against losses, lock in prices, or amplify gains and losses, so it can change a portfolio’s risk and potential return without owning the underlying asset directly.
weighted average price financial
"The price reported above reflects the weighted average price."
Weighted average price is the average price of a security where each trade or component is counted according to its size, so bigger trades pull the average more than smaller ones. Think of it like calculating the average cost of a grocery haul where items you bought more of have greater influence on the final per-item cost. Investors use it to understand the true average price paid or received, judge execution quality, and compare trading performance against market movement.
Rule 10b5-1 trading plan regulatory
"No transactions in this Form 4 are reported under a Rule 10b5-1 trading plan."
A Rule 10b5-1 trading plan is a pre-arranged schedule that allows company insiders to buy or sell stock at specific times, even if they have inside information. It helps prevent accusations of unfair trading by making these transactions look planned and transparent, rather than sneaky or illegal.
exercise price financial
"exercised stock options at an exercise price of $110.86 per share"
The exercise price is the fixed amount at which you can buy or sell an asset, like a stock, when using an options contract. It matters because it helps determine whether exercising the option will be profitable or not, depending on the current market price. Think of it as the set price you agree on today to buy or sell later.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What did UTHR director Nilda Mesa report in this Form 4?

She reported exercising stock options for 130 shares of UNITED THERAPEUTICS common stock at an exercise price of $110.86 per share, and selling 228 shares of common stock on September 14, 2026 at prices around $505.8 per share.

How many UTHR shares did Nilda Mesa sell in this filing?

She sold a total of 228 shares of UNITED THERAPEUTICS common stock: one sale of 130 shares at a weighted average price of $505.7868 and another sale of 98 shares at $505.9750 per share on September 14, 2026.

At what price were Nilda Mesa’s UTHR options exercised?

She exercised stock options covering 130 shares of UNITED THERAPEUTICS common stock at an exercise price of $110.86 per share. These options were originally granted with an expiration date of October 31, 2028.

How many UNITED THERAPEUTICS options does Nilda Mesa hold after these transactions?

After the option exercise reported in this Form 4, Nilda Mesa directly holds 6,430 stock options for UNITED THERAPEUTICS common stock, as shown in the derivative holdings following the transaction.

Were Nilda Mesa’s UTHR trades under a Rule 10b5-1 trading plan?

No. The filing indicates that the Rule 10b5-1 checkbox is not marked, so these UNITED THERAPEUTICS transactions are not reported as being made under a Rule 10b5-1 trading plan.

What does the footnote say about the UTHR sale price in this Form 4?

For the 130-share sale at $505.7868 per share, the footnote explains that the transaction was executed in multiple trades between $505.76 and $505.985, and that the reported price is a weighted average price.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google
Add on Google
Learn about SEC filing dates
SEC Form 4
FORM 4UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940
OMB APPROVAL
OMB Number:3235-0287
Estimated average burden
hours per response:0.5
Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.
1. Name and Address of Reporting Person*
Mesa Nilda

(Last)(First)(Middle)
C/O UNITED THERAPEUTICS CORPORATION
1000 SPRING STREET

(Street)
SILVER SPRING MARYLAND 20910

(City)(State)(Zip)

UNITED STATES

(Country)
2. Issuer Name and Ticker or Trading Symbol
UNITED THERAPEUTICS Corp [ UTHR ]
5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
XDirector10% Owner
Officer (give title below)Other (specify below)
2a. Foreign Trading Symbol
3. Date of Earliest Transaction (Month/Day/Year)
09/14/2026
6. Individual or Joint/Group Filing (Check Applicable Line)
XForm filed by One Reporting Person
Form filed by More than One Reporting Person
4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Year)2A. Deemed Execution Date, if any (Month/Day/Year)3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
CodeVAmount(A) or (D)Price
Common Stock09/14/2026M130A$110.866,560D
Common Stock09/14/2026S130D$505.7868(1)6,430D
Common Stock09/14/2026S98D$505.9755,580D
Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
(e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (Month/Day/Year)3A. Deemed Execution Date, if any (Month/Day/Year)4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 6. Date Exercisable and Expiration Date (Month/Day/Year)7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
CodeV(A)(D)Date ExercisableExpiration DateTitleAmount or Number of Shares
Stock Option$110.8609/14/2026M13010/31/201910/31/2028Common Stock130$0.006,430D
Explanation of Responses:
1. This transaction was executed in multiple trades at prices ranging from $505.76 to $505.985. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.
Remarks:
/s/ John S. Hess, Jr. under Power of Attorney09/15/2026
** Signature of Reporting PersonDate
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)

Keep reading